MARKET MOVERS
Bone-drug tests lift Amgen’s shares
Amgen Inc. of Thousand Oaks, Calif., had the best gain in the Standard & Poor’s 500. The world’s largest biotechnology company (with facilities in Cambridge and West Greenwich, R.I.) said its lead experimental product, a bone-strengthening drug called denosumab, did a better job in a clinical trial than Novartis AG’s Zometa to delay fractures in breast cancer patients whose illness had spread to the bones. 